Imlifidase Utilization in Glanzmann Thrombasthenia With Anti-GPIIb/IIIa and Anti-HLA Alloimmunization and Severe Platelet Refractoriness Following Hematopoietic Stem Cell Transplant

Mohammad AlNajjar^{1

2}, Ryan Rochat³, Amanda B Grimes², Amir Navaei^{4

5}, Todd Eagar⁶, Caridad Martinez^{1

2}, Khalid Yassine^{1

2}, Robert Krance^{1

2}, Saleh Bhar^{1

2

4}

Affiliations

¹ Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital, Houston, Texas, USA.
² Texas Children's Cancer and Hematology Centers, Baylor College of Medicine, Houston, Texas, USA.
³ Pediatric Infectious Disease, Baylor College of Medicine, Texas Children`s Hospital, Houston, Texas, USA.
⁴ Pediatric Critical Care Medicine, Baylor College of Medicine, Texas Children's Hospital, Houston, Texas, USA.
⁵ Blood Banking and Transfusion Medicine, Texas Children`s Hospital, Houston, Texas, USA.
⁶ Clinical Pathology and Genomics Medicine, HLA Laboratory, Methodist Hospital, Houston, Texas, USA.

Mohammad AlNajjar et al. Pediatr Blood Cancer. 2025 Mar.

. 2025 Mar;72(3):e31412.

doi: 10.1002/pbc.31412. Epub 2024 Nov 5.

Mohammad AlNajjar^{1

2}, Ryan Rochat³, Amanda B Grimes², Amir Navaei^{4

5}, Todd Eagar⁶, Caridad Martinez^{1

2}, Khalid Yassine^{1

2}, Robert Krance^{1

2}, Saleh Bhar^{1

2

4}

¹ Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital, Houston, Texas, USA.
² Texas Children's Cancer and Hematology Centers, Baylor College of Medicine, Houston, Texas, USA.
³ Pediatric Infectious Disease, Baylor College of Medicine, Texas Children`s Hospital, Houston, Texas, USA.
⁴ Pediatric Critical Care Medicine, Baylor College of Medicine, Texas Children's Hospital, Houston, Texas, USA.
⁵ Blood Banking and Transfusion Medicine, Texas Children`s Hospital, Houston, Texas, USA.
⁶ Clinical Pathology and Genomics Medicine, HLA Laboratory, Methodist Hospital, Houston, Texas, USA.

No abstract available

References

1. M. C. Poon, R. d'Oiron, R. B. Zotz, et al., “The International, Prospective Glanzmann Thrombasthenia Registry: Treatment and Outcomes in Surgical Intervention,” Haematologica 100, no. 8 (2015): 1038–1044, https://doi.org/10.3324/haematol.2014.121384.
1. M. Fiore, R. d'Oiron, X. Pillois, and M. C. Alessi, “Anti‐αIIb β3 Immunization in Glanzmann Thrombasthenia: Review of Literature and Treatment Recommendations,” British Journal of Haematology 181, no. 2 (2018): 173–182, https://doi.org/10.1111/bjh.15087.
1. C. Santoro, A. Rago, F. Biondo, et al., “Prevalence of Allo‐immunization Anti‐HLA and Anti‐integrin alphaIIbbeta3 in Glanzmann Thromboasthenia Patients,” Haemophilia 16, no. 5 (2010): 805–812, https://doi.org/10.1111/j.1365‐2516.2010.02230.x.
1. K. Ghosh, B. Kulkarni, S. Shetty, and S. Nair, “Antiplatelet Antibodies in Cases of Glanzmann's Thrombasthenia With and Without a History of Multiple Platelet Transfusion,” Indian Journal Human Genetics 15, no. 1 (2009): 23–27, https://doi.org/10.4103/0971‐6866.50866.
1. C. Gabe, K. C. Ziza, N. Durazzo, et al., “Detection of Alloimmunization in Glanzmann Thrombasthenia and Bernard‐Soulier Syndrome: Data From a Brazilian Center,” Hematology, Transfusion and Cell Therapy 45, no. 2 (2023): S101–S107, https://doi.org/10.1016/j.htct.2022.06.005.